BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 27902967)

  • 21. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
    Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
    Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
    Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
    Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
    [No Abstract]   [Full Text] [Related]  

  • 23. Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer.
    Zheng MW; Zhang CH; Chen K; Huang M; Li YP; Lin WT; Zhang RJ; Zhong L; Xiang R; Li LL; Liu XY; Wei YQ; Yang SY
    Mol Cancer Ther; 2016 Mar; 15(3):366-78. PubMed ID: 26721945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
    Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP
    Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tryptophan hydroxylase 1 and 5-HT
    Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA
    Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
    Kim S; Lee J; Jeon M; Lee JE; Nam SJ
    Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells.
    Liu CY; Huang TT; Chu PY; Huang CT; Lee CH; Wang WL; Lau KY; Tsai WC; Chao TI; Su JC; Chen MH; Shiau CW; Tseng LM; Chen KF
    Exp Mol Med; 2017 Aug; 49(8):e366. PubMed ID: 28798401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases.
    Kai K; Kondo K; Wang X; Xie X; Pitner MK; Reyes ME; Torres-Adorno AM; Masuda H; Hortobagyi GN; Bartholomeusz C; Saya H; Tripathy D; Sen S; Ueno NT
    Mol Cancer Ther; 2015 Dec; 14(12):2687-99. PubMed ID: 26443806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
    Lee J; Lim B; Pearson T; Choi K; Fuson JA; Bartholomeusz C; Paradiso LJ; Myers T; Tripathy D; Ueno NT
    Breast Cancer Res Treat; 2019 Jun; 175(2):339-351. PubMed ID: 30826934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
    Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY
    Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer.
    Jabbour-Leung NA; Chen X; Bui T; Jiang Y; Yang D; Vijayaraghavan S; McArthur MJ; Hunt KK; Keyomarsi K
    Mol Cancer Ther; 2016 Apr; 15(4):593-607. PubMed ID: 26826118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Midostaurin preferentially attenuates proliferation of triple-negative breast cancer cell lines through inhibition of Aurora kinase family.
    Kawai M; Nakashima A; Kamada S; Kikkawa U
    J Biomed Sci; 2015 Jul; 22(1):48. PubMed ID: 26141684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
    Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
    Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth.
    Rane C; Senapedis W; Baloglu E; Landesman Y; Crochiere M; Das-Gupta S; Minden A
    Sci Rep; 2017 Feb; 7():42555. PubMed ID: 28198380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
    Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
    BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.
    Ludwik KA; Campbell JP; Li M; Li Y; Sandusky ZM; Pasic L; Sowder ME; Brenin DR; Pietenpol JA; O'Doherty GA; Lannigan DA
    Mol Cancer Ther; 2016 Nov; 15(11):2598-2608. PubMed ID: 27528706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of Mitochondrial ERβ Expression Inhibits Triple-Negative Breast Cancer Tumor Progression by Activating Mitochondrial Function.
    Song IS; Jeong YJ; Jeong SH; Kim JE; Han J; Kim TH; Jang SW
    Cell Physiol Biochem; 2019; 52(3):468-485. PubMed ID: 30873822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
    Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
    Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.